Valuation: ImmuCell Corporation

Market Cap 10Cr 9.32Cr 8.62Cr 7.78Cr 15Cr 954.78Cr 15Cr 104.06Cr 41Cr 515.35Cr 38Cr 38Cr 1.63TCr P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 11Cr 10Cr 9.41Cr 8.49Cr 16Cr 1.04TCr 17Cr 113.62Cr 45Cr 562.7Cr 42Cr 41Cr 1.78TCr EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.83%
Yield 2024 *
-
Yield 2025 -
1 day-0.71%
1 week+10.40%
Current month+9.65%
1 month+4.65%
3 months+15.27%
6 months+13.52%
Current year+82.93%
1 week 10.5
Extreme 10.5
11.72
1 month 9.6
Extreme 9.6
11.72
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 01/11/2025
Director of Finance/CFO 47 07/04/2025
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 01/12/2013
Director/Board Member 61 31/03/2014
Director/Board Member 66 10/06/2020
Date Insider Type Main position Quantity % Market Cap. Importance
15/04/26 Free

Chairman

11,933 0.1319%
15/04/26 Free

Director

17,899 0.1979%
15/04/26 Free

Director

11,933 0.1319%
Change 5-day change 1-year change 3-year change Capi.($)
-0.71%+10.40%+146.71%+136.28% 10Cr
-2.32%-3.79%+34.24%+133.69% 1,26100Cr
-2.15%-2.75%+36.35%+82.05% 67TCr
-2.33%-3.04%+22.29%+106.80% 52TCr
-0.69%+0.37%+31.53%+69.78% 39TCr
-3.90%-6.39%+42.88%+35.41% 35TCr
-1.35%-0.95%+28.90%+56.34% 30TCr
-1.13%-1.80%+0.59%+33.00% 28TCr
-3.07%-5.17%+29.04%+67.26% 25TCr
-0.75%-0.44%+32.87%+123.96% 21TCr
Average -1.84%-0.09%+40.54%+84.46% 42TCr
Weighted average by Cap. -2.09%-2.12%+30.59%+91.57%

Financials

2024 2025
Net sales 2.65Cr 2.42Cr 2.23Cr 2.02Cr 3.8Cr 247.57Cr 3.95Cr 27Cr 11Cr 133.63Cr 9.94Cr 9.73Cr 421.96Cr 2.76Cr 2.52Cr 2.33Cr 2.1Cr 3.96Cr 258.32Cr 4.12Cr 28Cr 11Cr 139.43Cr 10Cr 10Cr 440.29Cr
Net income -21.57L -19.67L -18.19L -16.41L -30.91L -20Cr -32.13L -2.2Cr -86.82L -11Cr -80.91L -79.21L -34Cr -10.4L -9L -9L -8L -14.91L -9.72Cr -15.49L -1.06Cr -41.87L -5.25Cr -39.02L -38.2L -17Cr
Net Debt 1.13Cr 1.03Cr 95.64L 86.31L 1.63Cr 105.98Cr 1.69Cr 12Cr 4.57Cr 57Cr 4.25Cr 4.17Cr 180.64Cr 93.88L 85.61L 79.16L 71.44L 1.35Cr 88Cr 1.4Cr 9.56Cr 3.78Cr 47Cr 3.52Cr 3.45Cr 149.52Cr
Projected Income Statement - Annual - ImmuCell Corporation
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
18/26/18 $11.25 -0.71% 10,684
17/26/17 $11.33 -0.79% 18,535
16/26/16 $11.42 +6.23% 1,01,746
13/26/13 $10.75 +5.19% 40,752
12/26/12 $10.22 +0.29% 19,304
  1. Stock Market
  2. Stocks
  3. ICCC Stock